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502 - Emerging infections in neurological diseases
IMossl Transmissible spongiform encephalopathies (TSE) in
animals
J. Brugere-Picoux, H. Brugere
National Veterinary School ofAlfort, Maisons-Alfort, Frana
Prior 1985 naturally TSEs have been recognised in five animal species:
scrapie in sheep and in goat, transmissible mink encephalopathy, chronic
wasting disease in deer and elk.
Since 1985, TSEs have been reported in cattle, in domestic cats and in a
variety of other species of wild animals (cats and ruminants) maintained in
zoos and wild parks in Great Britain.
Scrapie is the prototype ofthe group ofthese TSEs and was not considered
as dangerous for man giving rise to the concept of the species barrier. At the
opposite, the bovine agent appeared to be able to cross numerous species
barriers including man. These facts justified numerous measures taken
progressively in all countries were the disease was recognised (sporadic or
enzootic form) especially after the crisis of march 1996.
Clinical diagnosis ofbovine spongiform encephalopathy (BSE) is difficult
and it is impossible to detect asymptomatic infected animals in the herd.
Confirmation of a clinical suspicion can be obtained with laboratory
examination after the death of the animal. Improvement of the epidemio-
logical survey with the mean of tests in the slaughterhouses lose an increased
safety for the consumer. These tests will be extended to all groups ofanimals
at risk (found dead, emergency slaughter). An experience ofthis method was
first made in Switzerland. The last problem is the hypothesis ofinfection of
sheep with the BSE agent.
IMoS71 lorna disease virus infections are involved in mood
disorders of man and behavioural diseases of animals
L. Bode', H. Ludwig2
'Robert Koch-Institute; zFree University oflkrlin, Berlin, Germany
Objectives: Prevalence of viral markers, isolates, and therapeutic
approaches, supporting a Link ofBornavirus (BDV) with human depression
analogously to animal Borna disease.
Methods: Detection methods are antibodies in serum and antigens and
nucleic acid in leucocytes, the isolation of infectious virus from positive
leucocytes, in vitro studies of antiviral compounds, and point prevalence as
well as longitudinal follow-ups ofdepressed patients and diseased animals.
Results: BDV, .ilIl ululful; cllvdupcd, negative and si..ngk-stralldl:d RNA
virus of the new family Bornaviridae, is an evolutionary old virus infecting
farm animals, pets (e.g. horses, sheep, cattle, cats), and man. Primary target
cells are neurons ofthe limbic system, but also other cells ofthe brain and the
blood, establishing a persistent non - cytopathogenic infection which
alternates between "latent" and activated states. Possibly, viral components
disturb the balance ofthe neurotransmitter network. In infected animals, e.g.
horses, a relapsing mainly apathetic syndrome has frequently been observed.
In humans, an association with recurrent mood disorders, but also other
diseases of the limbic system, is internationally under debate. Evidence came
from frequent findings of serum antibodies, viral components in blood
leucocytes, from proteins in cerebrospinal fluid of patients with acute
depressive illness, and from a few human Bornaviruses which could have
been isolated so far, in Germany and japan. Despite low genetic divergence,
there are significant biological differences between natural and laboratory
BDV strains (e.g. drug sensitiviry or resistance).
Condusions: BDV is an old virus which is now being recognised as potential
hazard for human mental health.
IMossl West Nile virus infection: A reemerging fatal
arbovirosis
Vincent Deubel
Departmrnt of Virology, Institut Pasteur, Paris, France
Objectives: West Nile virus (WNV) is an arthropod-borne virus of the
family Flaviviridae. WNV is endemic in all Africa, Middle East and Asia. It
circulates periodically in southern and southeastern Europe and has recently
been introduced in the USA. Whether local transmission cycles or repeated
viral introductions from other enzootic areas by migratory birds prevail in
European countries remains unknown.
Methods: Because WNV has a wide geographical distribution, regional
variations among strains of WNV have been investigated on genetic,
phenotypic and epidemiologic bases.
Results: Phylogenetic trees resulting from analyses of sequences for a
portion of the E genc including 40 WN virus strains showed that viruses
segregated in two lineages. Lineage I includes isolates from Africa and all
strains from Europe, Israel and the USA. Lineage II is composed only of
strains isolated in Africa. Thus. a combination of introduction ofWNV by
chronically infected birds from sub-Saharan Africa to southern Europe and
of virus persistence in disease-endemic foci may occur.
Under experimental infection in rodents. WNV can invade the central
nervous system (CNS) via several routes. Inflammatory changes in the CNS
ofinfected mice vary depending on the host and the virus strain. In animals
which succumb to a rapid infection there is a reduced inflammatory effect in
the CNS, due to the lack of time for changes to occur. Immunohistochem-
istry and electron microscopy studi~ reveal extensive replication and
cytopathology occurring in neurons.
Conclusion: Our study underlin~ the role ofbirds and possibly mosquitoes
and humans in the dissemination ofWNV.
S03 - Hepatitis Band C; natural history...
IMoS10I Acute and chronic HBV Infection in transgenic mice
model
M. Chen I, M. Sallberg l , A. Birkett2, j. jones2, J. Hughes2, D. Milichz
IKarolinska Institute, Stockholm, Sweden; zImmune Complex Corporation, San
Diego, CA, United States
To better understand T cell activation and T cell tolerance induction by the
nucleoprotein antigens of HBV, several lineages of HBc/HBeAg-specific
CD4 + TCR transgenic (Tg) mice were produced. The TCR genes were
derived from T cell hybridomas produced from either wild-type mice
immunized with HBeAg or from HBeAg-Tg mice. The CD4+ T cells
present in the TCR-Tg lineages derived from wild-type mice were never
exposed to the HBc/HBeAgs, are of relatively high affinity and represent
naive populations similar to an HBc/HBeAg-specific repertoire during an
acute infection. In contrast, the CD4 + T cells present in the TCR mice
derived from HBeAg-Tg mice are HBc/HBeAg-specific populations which
were selected in the presence of circulating HBeAg, are of relatively low
affinity and may serve as a model for the CD4 + repertoire during chronic
infections.
The acute-like TCR-Tg lineages differ markedly from the chronic-like
TCR-Tg lineages with respect to the (1) affiniry and kinetics of T cell
activation; (2) preferential recognition of the HBc and HBe antigens; (3) in
vitro and i,1 vivo immune responsiveness; (4) Thl/Th2 subset differentiation;
(5) clonal deletion as analyzed in (TCR-Tg x HBc/HBeAg-Tg) "double
Tg" mice; and most importantly (6) the kinetics and severity ofliver injury
occurring after adoptive transfcr into HBc and/or HBeAg-Tg recipients.
The TCR-Tg and TCR x HBc/HBeAg-double Tg systems are providing
unique insights into the complex interactions berween HBV and the host
immune response.
IMoS111 Treatment of hepatitis Cvirus Infection
O. Weiland
Division of Infectious Diseases, Karolinska Institutet, Huddinge University
Hospital, Huddinge, Sweden
Treatment outcome for patients with chronic hepatitis C virus (HCV)
infection has improved substantially during recent years with the develop-
ment oflFN and ribavirin combination therapy.
Combination therapy with IFN-alfa 3 MU t.i.w. plus ribavirin 1000-
1200 mg daily in two divided doses for 6-12 months significantly improves
the biochemical and virological sustained response (SR) rates 2-3 times as
compared to IFN monotherapy given during 12 months. Hence, combina-
tion therapy has become standard therapy both for for naIve and relapse
patients. For genotype 2 and 3 patients 6 months combination therapy is
sufficient whereas genotype 1 patients with high baseline viral load (> 3
million copies/rn1 serum) will need 48 weeks treatment. For the latter group
treatment is still not satisfactory since only 30% will achieve virological SR.
For genorype 2 and 3 patients nearly 70% virological SR rates can be
achieved with 6 months combination therapy provided cirrhosis is not
established. Patients with cirrhosis rcspond less well.
